Genmab — Juni 2017

[Sukkeralf]

Nu er der da noget at studere i weekenden - vi må grave nogel resultater op fra andre kandidater

[E_L]

ow ok Mcjean, haha, keeping the excitement here then lol

[E_L]

but lets forget about Dara anyway now, it is all about solid tumours from now on #optimist

[E_L]

what are your first thoughts on those results? it doesnt really say what sort of response the patients had
...

[Mcjean]

Since they want to present it on an upcoming medical konference, it can be that bad:-)

[Solsen]

As I recall the pts was some kind late stage. So its hard to say its not good. Cervical had very good preclinical results. I think we have to wait and se.

[Mcjean]

And if they finish recruting same time we can expect the other studies soon maybe?

[Solsen]

7 pts still ongoing is good.

[Mcjean]

This one was big with 34 of 173 in seven different types, so maybe the other one are even better maybe but pure speculation.

[Solsen]

I expectet the best results in cervical and ovary cancer....

[Sukkeralf]

I protokollen står der stage Ib or less, så umiddelbart ikke så syge - det undrer mig dog lidt

[Sukkeralf]

Det er nok en god ide at kigge lidt grundigt på dette, for man kan nok let overse et eller andet.

[Solsen]

Drugs Approved for Cervical Cancer

This page lists cancer drugs approved by the Food and Drug Administration (FDA) for cervical cancer. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. The drug names link to NCI's Cancer Drug Information summaries.

(www.cancer.gov)

[Solsen]

Godt set sukker. Har vi mon ikke en poster fra de allerførste data mon.

[Helge_LarsenPI-redaktør]

Siden findes ikke

(borsen.dk)

[Solsen]

http://www.medscape.com/viewarticle/842038#vp_1 Lidt om Avastin.

[Solsen]

Mon ikke man overvejer et evt kombiforsøg...

[Solsen]

..og hvorfor ikke dara

[Solsen]

http://files.shareholder.com/downloads/AMDA-KPIBN/3968132968x0x832683/D1560CA8-68E1-49D1-ACB5-D5072F83B6E5/2015_ASCO_TF-ADC_GEN701_Lassen_poster_FINAL.pdf "Advanced cancer" i fase 1 forsøget

[Solsen]

Inclusion Criteria:

• Patients with relapsed, advanced and/or metastatic cancer who have failed available standard treatments or who are not candidates for standard therapy.